# PRIME: Pilot Study Evaluating Percutaneous Vaccination of BCG for Bladder Cancer

> **NCT02326168** · EARLY_PHASE1 · COMPLETED · sponsor: **The University of Texas Health Science Center at San Antonio** · enrollment: 25 (actual)

## Conditions studied

- Bladder Cancer

## Interventions

- **DRUG:** Bacillus Calmette-Guerin (BCG)

## Key facts

- **NCT ID:** NCT02326168
- **Lead sponsor:** The University of Texas Health Science Center at San Antonio
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10
- **Primary completion:** 2015-10
- **Final completion:** 2015-10
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2017-01-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02326168

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02326168, "PRIME: Pilot Study Evaluating Percutaneous Vaccination of BCG for Bladder Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02326168. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*